VolitionRx (NYSE:VNRX) Earns Hold Rating from Benchmark

Benchmark restated their hold rating on shares of VolitionRx (NYSE:VNRX) in a report published on Friday,Benzinga reports.

Separately, StockNews.com began coverage on VolitionRx in a report on Wednesday, November 20th. They set a “sell” rating for the company.

VolitionRx Trading Down 2.1 %

Shares of VNRX opened at $0.79 on Friday. The firm’s fifty day simple moving average is $0.69 and its 200-day simple moving average is $0.68. The firm has a market capitalization of $73.57 million, a price-to-earnings ratio of -2.21 and a beta of 1.10. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.